We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current BCRX market cap is 1.52B. The company's latest EPS is USD -1.0937 and P/E is -6.69.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 86.74M | 93.4M | 92.76M | 109.33M | 117.09M |
| Operating Income | -19.26M | -42.67M | -14.49M | 8.76M | 7.69M |
| Net Income | -36.15M | -61.73M | -35.38M | -12.67M | -14.03M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 48.84M | 17.81M | 157.17M | 270.83M | 331.41M |
| Operating Income | -99.46M | -174.76M | -177.72M | -148.44M | -103.71M |
| Net Income | -108.9M | -182.81M | -184.06M | -247.12M | -226.54M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 522.92M | 516.96M | 467.89M | 472.42M | 491.25M |
| Total Liabilities | 933.91M | 972.49M | 944.06M | 948.03M | 959.82M |
| Total Equity | -410.99M | -455.53M | -476.17M | -475.61M | -468.56M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 175.28M | 334.72M | 588.15M | 550M | 516.96M |
| Total Liabilities | 137.03M | 353.98M | 695.14M | 844.6M | 972.49M |
| Total Equity | 38.25M | -19.26M | -106.99M | -294.6M | -455.53M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -86.22M | -95.14M | -53.68M | -55.05M | -46.81M |
| Investing | -103.03M | -131.5M | 28.76M | 26.31M | 34.8M |
| Financing | 35.66M | 32.49M | -1.05M | -3.01M | -1.74M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -89.58M | -137.22M | -142.16M | -161.85M | -95.14M |
| Investing | 77.93M | -6.86M | 15.8M | -128.24M | -131.5M |
| Financing | 99.1M | 302.7M | 359.67M | 88.03M | 32.49M |
| Market Cap | 1.52B |
| Price to Earnings Ratio | -6.69 |
| Price to Sales Ratio | 4.58 |
| Price to Cash Ratio | 13.7 |
| Price to Book Ratio | -3.33 |
| Dividend Yield | - |
| Shares Outstanding | 207.13M |
| Average Volume (1 week) | 1.73M |
| Average Volume (1 Month) | 1.8M |
| 52 Week Change | 18.83% |
| 52 Week High | 8.88 |
| 52 Week Low | 4.03 |
| Spread (Intraday) | 0.5 (6.67%) |
| Company Name | BioCryst Pharmaceuticals Inc |
| Address |
2711 centerville road wilmington, delaware 19808 |
| Website | https://www.biocryst.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
